Devyser launches a new updated NGS assay to simplify thalassemia testing
Devyser has launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution designed...
Thank you for requesting one of our whitepapers.
Devyser Thalassemia achieves 99.9% sensitivity: Insights from a recent study
Thalassemia and hemoglobinopathies are among the most common genetic disorders worldwide, affecting...
Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK
Webinar recap: Implementing Devyser BRCA to evaluate hereditary cancer risk
Hereditary cancers, particularly breast and ovarian cancers, pose a significant risk for many...